Skip to main content

Research Repository

Advanced Search

Glutamate dehydrogenase (GLUD1) expression in breast cancer

Craze, Madeleine L.; El-Ansari, Rokaya; Aleskandarany, Mohammed A.; Cheng, Kiu Wai; Al-Farsi, Lutfi; Masisi, Brendah; Diez-Rodriguez, Maria; Nolan, Christopher C; Ellis, Ian O; Rakha, Emad A; Green, Andrew R

Glutamate dehydrogenase (GLUD1) expression in breast cancer Thumbnail


Authors

Madeleine L. Craze

Rokaya El-Ansari

Mohammed A. Aleskandarany

Kiu Wai Cheng

Lutfi Al-Farsi

Brendah Masisi

Maria Diez-Rodriguez

Christopher C Nolan

EMAD RAKHA Emad.Rakha@nottingham.ac.uk
Professor of Breast Cancer Pathology



Abstract

Dysregulated cellular metabolism is regarded as one of the hallmarks of cancer with some tumours utilising the glutamine metabolism pathway for their sustained proliferation and survival. Glutamate dehydrogenase (GLUD1) is a key enzyme in glutaminolysis converting glutamate to α-Ketoglutarate for entry into the TCA cycle.
Breast cancer (BC) comprises a heterogeneous group of tumours in terms of molecular biology and clinical behaviour, and we have previously shown that altered glutamine metabolism varies substantially among the different molecular subtypes.
We hypothesise that the prognostic value of GLUD1 expression will differ between the BC molecular subtypes and may act as a potential therapeutic target for BC tumours.
Methods: GLUD1 was assessed at the DNA, mRNA (n=1,980) and protein (n=1,300) levels in large and well-characterised cohorts and correlated with clinicopathological parameters, molecular subtypes, patient outcome and treatments.
Results: There was a correlation between GLUD1 mRNA and GLUD1 protein expression which were highly expressed in low grade Luminal/ER+ BC (p

Citation

Craze, M. L., El-Ansari, R., Aleskandarany, M. A., Cheng, K. W., Al-Farsi, L., Masisi, B., …Green, A. R. (2019). Glutamate dehydrogenase (GLUD1) expression in breast cancer. Breast Cancer Research and Treatment, 174(1), 79–91. https://doi.org/10.1007/s10549-018-5060-z

Journal Article Type Article
Acceptance Date Nov 16, 2018
Online Publication Date Nov 23, 2018
Publication Date 2019-02
Deposit Date Nov 19, 2018
Publicly Available Date Nov 24, 2019
Journal Breast Cancer Research and Treatment
Print ISSN 0167-6806
Electronic ISSN 1573-7217
Publisher Springer Verlag
Peer Reviewed Peer Reviewed
Volume 174
Issue 1
Pages 79–91
DOI https://doi.org/10.1007/s10549-018-5060-z
Keywords GLUD1; breast cancer; prognosis; triple negative; glutamine; metabolism
Public URL https://nottingham-repository.worktribe.com/output/1281768
Publisher URL https://link.springer.com/article/10.1007%2Fs10549-018-5060-z
Additional Information Received: 9 November 2018; Accepted: 16 November 2018; First Online: 23 November 2018; : ; : The authors confirm that they do not have any conflict of interests to declare.; : This study was approved by the Nottingham Research Ethics Committee 2 under the title ‘Development of a molecular genetic classification of breast cancer’. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All tissue samples from Nottingham used in this study were pseudo-anonymised and collected prior to 1st September 2006; therefore under the Human Tissue Act informed patient consent was not needed. Release of data was also pseudo-anonymised as per Human Tissue Act regulations. This article does not contain any studies with animals performed by any of the authors.
Contract Date Nov 19, 2018

Files








You might also like



Downloadable Citations